3 completed, 1 suspended. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Suspended 1 |
| Phase 2 | 2 | Completed 2 |
Follow Enteropathy Associated T-cell Lymphoma: new trials by email Literature Review of Enteropathy Associated T-cell Lymphoma trials Research Report on Enteropathy Associated T-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. Brentuximab Vedotin - Enteropathy Associated T-cell Lymphoma | Phase 2 | Completed | Imagine Institute | 14 | 2018-02-07 | 2024-06-20 |
| A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Brentuximab vedotin - T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | Deepa Jagadeesh | 23 | 2016-06-17 | 2025-11-21 |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies Alisertib - B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 58 | 2008-07-11 | 2019-05-31 |
Enteropathy-Associated T-Cell Lymphoma (4) · Immunoblastic Lymphadenopathy (3) · Lymphoma, Large-Cell, Anaplastic (2) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Multiple Myeloma (1) · Mycosis Fungoides (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma, Non-Hodgkin (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphadenopathy (3) · Lymphoma (3) · Lymphoma, T-Cell (3) · Hematologic Diseases (2) · Leukemia, Lymphoid (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1)
Brentuximab Vedotin (2) · Cyclophosphamide (1) · MLN 8237 (1) · fludarabine (1)
Deepa Jagadeesh (1) · Imagine Institute (1) · Millennium Pharmaceuticals, Inc. (1) · National Cancer Institute (NCI) (1)
United States (3) · France (1)
Deepa Jagadeesh, MD, MPH (1) · Hermine Olivier (1) · Paolo Caimi, MD (1) · Samuel Y Ng, M.D. (1)